Epigenomics AG
Epigenomics AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative molecular diagnostics for cancer detection. Founded in 1998, the company has established itself as a leader in the field of epigenetics, particularly with its flagship product, Epi proColon, which is designed for non-invasive colorectal cancer screening. With a strong presence in Europe and North America, Epigenomics AG is committed to advancing personalised medicine through its unique biomarker-based technologies. The company has achieved significant milestones, including regulatory approvals and partnerships that enhance its market position. By leveraging cutting-edge research and development, Epigenomics AG continues to drive advancements in cancer diagnostics, making a meaningful impact on patient care and outcomes.
DitchCarbon Score
How does Epigenomics AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Epigenomics AG's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Epigenomics AG's reported carbon emissions
Epigenomics AG, headquartered in Germany, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any documented reduction targets or climate pledges. As a result, there is no information on their Scope 1, 2, or 3 emissions, nor any significant achievements in carbon reduction initiatives. The absence of emissions data and climate commitments suggests that Epigenomics AG may still be in the early stages of developing a comprehensive sustainability strategy. In the context of the industry, it is increasingly important for companies to set measurable climate targets and report emissions transparently to align with global climate goals. Without such commitments, Epigenomics AG may face challenges in demonstrating its environmental responsibility and sustainability efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Epigenomics AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
